Mark G. Frattini
- Molecular Biology top 5%
- Hematology top 0.5%
- Epidemiology top 5%
- Oncology top 5%
- Immunology top 5%
- Co-authors
- Laimonis A. LaiminsCraig MeyersJohn B. HudsonAnthony LetaiCourtney D. DiNardoHagop M. KantarjianSteven L. DreslerDaniel A. Pollyea
- Topics
- Acute Myeloid Leukemia Research (25 papers)Chronic Myeloid Leukemia Treatments (12 papers)DNA Repair Mechanisms (11 papers)
- Cited by
- HematologyGeneticsOncology
- Partner nations
- United StatesFranceAustralia
In The Last Decade
Mark G. Frattini
75 papers receiving 3.3k citations
Hit Papers
Peers
Comparison fields: 5 of 91
- Molecular Biology 1.8k
- Hematology 1.3k
- Epidemiology 893
- Oncology 890
- Immunology 538
Countries citing papers authored by Mark G. Frattini
This map shows the geographic impact of Mark G. Frattini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark G. Frattini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark G. Frattini more than expected).
Fields of papers citing papers by Mark G. Frattini
This network shows the impact of papers produced by Mark G. Frattini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark G. Frattini. The network helps show where Mark G. Frattini may publish in the future.
Co-authorship network of co-authors of Mark G. Frattini
This figure shows the co-authorship network connecting the top 25 collaborators of Mark G. Frattini. A scholar is included among the top collaborators of Mark G. Frattini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark G. Frattini. Mark G. Frattini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 22 | |
| 2 | 21 | |
| 3 | 127 | |
| 4 | 18 | |
| 5 | 79 | |
| 6 | 74 | |
| 7 | 35 | |
| 8 | 1 | |
| 9 | Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b studybreakdown → | 498 |
| 10 | 8 | |
| 11 | 10 | |
| 12 | 266 | |
| 13 | 11 | |
| 14 | 19 | |
| 15 | 1 | |
| 16 | 18 | |
| 17 | 27 | |
| 18 | 60 | |
| 19 | 70 | |
| 20 | 15 |
About Mark G. Frattini
Mark G. Frattini is a scholar working on Hematology, Genetics and Oncology, having authored 75 papers that have together received 3.4k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (25 papers), Chronic Myeloid Leukemia Treatments (12 papers) and DNA Repair Mechanisms (11 papers). The work is most often cited by research in Hematology (1.3k citations), Genetics (361 citations) and Oncology (890 citations). Mark G. Frattini has collaborated with scholars based in United States, France and Australia. Frequent co-authors include Laimonis A. Laimins, Craig Meyers, John B. Hudson, Anthony Letai, Courtney D. DiNardo, Hagop M. Kantarjian, Steven L. Dresler, Daniel A. Pollyea, Andrew H. Wei and Keith W. Pratz. Their work appears in journals such as Science, Cell and Proceedings of the National Academy of Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.